NDC 0069-1751

Talzenna

Talazoparib

Talzenna is a Oral Capsule in the Human Prescription Drug category. It is labeled and distributed by Pfizer Laboratories Div Pfizer Inc. The primary component is Talazoparib Tosylate.

Product ID0069-1751_0a4af2c6-fb47-4122-b94c-dc24945e3be0
NDC0069-1751
Product TypeHuman Prescription Drug
Proprietary NameTalzenna
Generic NameTalazoparib
Dosage FormCapsule
Route of AdministrationORAL
Marketing Start Date2022-01-31
Marketing CategoryNDA /
Application NumberNDA211651
Labeler NamePfizer Laboratories Div Pfizer Inc
Substance NameTALAZOPARIB TOSYLATE
Active Ingredient Strength1 mg/1
Pharm ClassesPoly(ADP-Ribose) Polymerase Inhibitor [EPC], Poly(ADP-Ribose) Polymerase Inhibitors [MoA]
NDC Exclude FlagN
Listing Certified Through2023-12-31

Packaging

NDC 0069-1751-30

1 BOTTLE in 1 CARTON (0069-1751-30) > 30 CAPSULE in 1 BOTTLE
Marketing Start Date2022-01-31
NDC Exclude FlagN
Sample Package?N

Drug Details

NDC Crossover Matching brand name "Talzenna" or generic name "Talazoparib"

NDCBrand NameGeneric Name
0069-0296Talzennatalazoparib
0069-1195Talzennatalazoparib
0069-1501Talzennatalazoparib
0069-1751Talzennatalazoparib
46014-0296Talzennatalazoparib
46014-1195Talzennatalazoparib
63539-295Talzennatalazoparib

Trademark Results [Talzenna]

Mark Image

Registration | Serial
Company
Trademark
Application Date
TALZENNA
TALZENNA
87293680 not registered Dead/Abandoned
Wyeth LLC
2017-01-09
TALZENNA
TALZENNA
86253764 5291322 Live/Registered
Wyeth LLC
2014-04-16
TALZENNA
TALZENNA
85173532 not registered Dead/Abandoned
Wyeth LLC
2010-11-10
TALZENNA
TALZENNA
77180181 not registered Dead/Abandoned
WYETH LLC
2007-05-14

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.